- Conditions
- Hematological Malignancies
- Interventions
- Haploidentical Allogeneic Transplantation
- Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 1,109
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Pack Health's digital life coaching (DLC)
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
- Interventions
- BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4, SCT
- Biological · Drug · Procedure
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2032
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Buffalo, New York • New York, New York + 4 more
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Beta-Thalassemia, Transfusion Dependent Beta-Thalassaemia
- Interventions
- autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452
- Biological · Device
- Lead sponsor
- Daniel Bauer
- Other
- Eligibility
- 13 Years to 40 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia
- Interventions
- recombinant interferon alfa, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, imatinib mesylate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 3
- States / cities
- Duarte, California • Seattle, Washington
- Conditions
- Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
- Interventions
- Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC
- Device · Other
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 4 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, T-Cell Non-Hodgkin Lymphoma
- Interventions
- Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant, Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells, Total Nodal Irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Robert Lowsky
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hematologic Diseases, Acute-graft-versus-host Disease, Leukemia, Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma
- Interventions
- Sirolimus, Mycophenolate mofetil (MMF), Carmustine, Etoposide, Cyclophosphamide (Cyclo, CY), FTBI
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute, Myeloproliferative-Myelodysplastic Diseases, Lymphoma, Malignant
- Interventions
- Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients, Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies, Hematopoietic Progenitor Cell Transplantation (HPCT), CNS radiation treatment for ALL with prior CNS disease patients
- Drug · Other · Radiation
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Graft-Versus-Host Disease (cGVHD)
- Interventions
- Vimseltinib
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 26
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 22 more
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Myelodysplastic Syndrome
- Interventions
- Busulfan, Cyclophosphamide, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation
- Drug · Procedure · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 5 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
- Interventions
- Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant, Total Body Irradiation, Sirolimus Pill, Mycophenolate Mofetil
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma, Myeloma
- Interventions
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate Mofetil (MMF), Hematopoietic Stem Cell Transplant (HSCT)
- Radiation · Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclosporine, fludarabine phosphate, methotrexate, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Hodgkin Lymphoma, Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
- Interventions
- CliniMACS, Stem cell transplantation, Fludarabine, Thioplex®, L-phenylalanine mustard, Mycophenolate mofetil, Rituxan™, Alemtuzumab, Cyclophosphamide, Anti-thymocyte globulin (Rabbit), G-CSF, Muromonab
- Device · Procedure · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Tagraxofusp-erzs
- Drug · Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- Bone Marrow Transplant Complications, Hematologic Malignancy
- Interventions
- BMT-CARE, Usual Care
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Tampa, Florida • Boston, Massachusetts
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Fanconi Anemia, Aplastic Anemia
- Interventions
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 4 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2018
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia (CML), Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myeloproliferative Disorders
- Interventions
- POL6326, Leukapheresis, PBSC Transplant
- Drug · Procedure
- Lead sponsor
- Polyphor Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • St Louis, Missouri
- Conditions
- B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
- Interventions
- Cyclosporine, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Total-Body Irradiation
- Drug · Procedure · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, SCD
- Interventions
- Fludarabine, Hematopoietic Stem Cell Transplant (HSCT)
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Drug · Biological
- Lead sponsor
- Sawa Ito, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Primary Myelofibrosis, Secondary Myelofibrosis
- Interventions
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Melphalan, Mycophenolate Mofetil, Tacrolimus, Total-Body Irradiation
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fanconi Anemia
- Interventions
- CD34+ selected cells
- Biological
- Lead sponsor
- Neena Kapoor, M.D.
- Other
- Eligibility
- 8 Weeks to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California